Sunitinib treatment of unresectable malignant pheochromocytoma and paraganglioma
Not Applicable
- Conditions
- malignant pheochromocytoma malignant paraganglioma
- Registration Number
- JPRN-UMIN000006579
- Lead Sponsor
- Department of Urology, Kyoto University, Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
1) Brain metastasis 2) Existence of other malignancy before registration for less than 5 years. 3) Treatment history with other tyrosine kinase inhibitors or anti-angiogenic drugs. 4) Severe liver dysfunction; Child-Pugh classification C 5) History of previous hypersensitivity for an ingredient of sutent. 6) The women who has possibility of or hopes for the pregnancy.Breast-feeding mother. The men who hopes for the pregnancy of a partner. 7) Difficulty in participating to an study due to psychiatric disorders. 8) The case that Chief Researcher or doctor judge as unsuitable for enrollment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse event/Side effect Disease control rate
- Secondary Outcome Measures
Name Time Method Time to treatment failure Response Rate